PPARA and early-onset autosomal dominant Alzheimer disease: PPAR ligands are being considered also for their therapeutic potential in the control of metabolic disorders (i.e., hyperlipidaemia), atherosclerosis and for the treatment of the Alzheimer’s disease [47,48].